These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27569750)

  • 21. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
    Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
    Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
    Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis.
    Arends S; Lebbink HR; Spoorenberg A; Bungener LB; Roozendaal C; van der Veer E; Houtman PM; Griep EN; Limburg PC; Kallenberg CG; Wolbink GJ; Brouwer E
    Clin Exp Rheumatol; 2010; 28(5):661-8. PubMed ID: 20822711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
    Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Coelho R; Tavares P; Soares J; Sousa AL; Carvalho D; Sousa P; da Silva JP; Meira T; Silva Ferreira F; Dias CC; Chowers Y; Ben-Horin S; Magro F;
    Therap Adv Gastroenterol; 2016 Nov; 9(6):781-794. PubMed ID: 27803733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
    Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
    J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.
    Kestens C; van Oijen MG; Mulder CL; van Bodegraven AA; Dijkstra G; de Jong D; Ponsioen C; van Tuyl BA; Siersema PD; Fidder HH; Oldenburg B;
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):826-31. PubMed ID: 23376000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier.
    Kharlamova N; Hermanrud C; Dunn N; Ryner M; Hambardzumyan K; Vivar Pomiano N; Marits P; Gjertsson I; Saevarsdottir S; Pullerits R; Fogdell-Hahn A
    Front Immunol; 2020; 11():1365. PubMed ID: 32793189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
    Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
    Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry.
    Jourdil JF; Némoz B; Gautier-Veyret E; Romero C; Stanke-Labesque F
    Ther Drug Monit; 2018 Aug; 40(4):417-424. PubMed ID: 29608486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surface plasmon resonance assays for the therapeutic drug monitoring of infliximab indicate clinical relevance of anti-infliximab antibody binding properties.
    Grasmeier MK; Weber S; Treiber M; Thaler MA; Luppa PB
    Clin Chem Lab Med; 2023 Jun; 61(7):1255-1265. PubMed ID: 36753693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions.
    Brugnolo F; Annunziato F; Sampognaro S; Campi P; Manfredi M; Matucci A; Blanca M; Romagnani S; Maggi E; Parronchi P
    J Immunol; 1999 Jul; 163(2):1053-9. PubMed ID: 10395704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.
    Kotze PG; Yamamoto T; Danese S; Suzuki Y; Teixeira FV; de Albuquerque IC; Saad-Hossne R; de Barcelos IF; da Silva RN; da Silva Kotze LM; Olandoski M; Sacchi M; Yamada A; Takeuchi K; Spinelli A
    J Crohns Colitis; 2015 Jul; 9(7):541-7. PubMed ID: 25820017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human atopen-specific types 1 and 2 T helper cell clones.
    Wierenga EA; Snoek M; Jansen HM; Bos JD; van Lier RA; Kapsenberg ML
    J Immunol; 1991 Nov; 147(9):2942-9. PubMed ID: 1680923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases.
    Martínez-Feito A; Novella-Navarro M; Hernández-Breijo B; Nozal P; Peiteado D; Villalba A; Nuño L; Monjo I; Pascual-Salcedo D; Balsa A; Plasencia-Rodríguez C
    Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38175741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of infliximab and adalimumab for ambulatory Crohn's disease patients in primary gastroenterology centres.
    Tursi A; Elisei W; Picchio M; Penna A; Lecca PG; Forti G; Giorgetti G; Faggiani R; Zampaletta C; Pelecca G; Brandimarte G
    Eur J Intern Med; 2014 Jun; 25(5):485-90. PubMed ID: 24631020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
    Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC
    J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of aspirin desensitization on T-cell cytokines and plasma lipoxins in aspirin-exacerbated respiratory disease.
    Aksu K; Kurt E; Alatas Ö; Gülbas Z
    Allergy Asthma Proc; 2014; 35(2):148-55. PubMed ID: 24717792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.